WHEN DECISIONS MATTER IN BREAST CANCER

Providing accurate, personalized information for women facing important questions about cancer

Hereditary cancer **risk assessments and genetic testing** delivers critical answers – providing women with power and control over their future.

Am I at risk for breast cancer?

myRisk® helps doctors understand a woman's risk of developing breast cancer using genetic testing and family history. The test provides medical society guidelines for your doctor in a simple and easy-to-use report.*

riskScore™ now included with Myriad **myRisk,** provides actionable results for women who are negative for a genetic mutation associated with a hereditary breast cancer**

Should I treat my breast cancer?

Now, patients diagnosed with ER+, HER2–, early-stage breast cancer have the most advanced and effective test to predict breast cancer recurrence.

EndoPredict® ***identifies low-risk women who can safely forego chemotherapy, and help maintain quality of life.***

Who should get an Endopredict test?

- Newly Diagnosed Early-Stage Breast Cancer
- ER+
- HER2–
- Node Negative or Node Positive
- Pre- or Post-Menopausal

myriad®

OVER 25 YEARS

When decisions matter women can rely on the quality of Myriad's products.

Myriad is committed to providing answers to critical questions that add personalization to both cancer **management and treatment.**

myRisk® is a 28-gene DNA panel that identifies an elevated risk for eight hereditary cancers.

Women who test positive for a hereditary cancer mutation face a greater risk for cancer than the general population.

Breast Cancer Risk	Ovarian Cancer Risk	Uterine Cancer Risk	Increased Risk
up to 11X	up to 44X	up to 47X	for Melanoma, Pancreatic and Colon Cancer

Management Recommendations for Patients with Hereditary Risk:

Prevention or early detection of cancer is key. Therefore, increased screening, per medical guidelines* is recommended.

How should I treat my cancer?

Research and development of companion diagnostics provides answers to critical questions and can advance the personalization of breast cancer treatment.

BRACAnalysis CDx® is a companion diagnostic test that detects germline *BRCA1* and *BRCA2* mutations and helps indicate whether or not patients with cancer may preferentially benefit from the PARP inhibitors Lynparza® (olaparib) and Zejula® (niraparib).

myChoice® HRD is a test that assesses a cancer's ability to repair DNA damage. The results will help doctors identify more patients who may preferentially benefit from DNA-damaging medicines and PARP inhibitors.

Myriad is committed to research – 9 ongoing studies in breast cancer.

If you are a patient or caregiver of someone recently diagnosed with breast cancer, talk to your doctor or visit ***myriad.com*** *to learn more about genetic testing.*

Take a 30-second quiz to learn more about your hereditary cancer risk http://www.HCQuiz.com

HEREDITARY CANCER QUIZ™ by MYRIAD GENETICS

Learn more at Myriad.com

myriad® WHEN DECISIONS MATTER

For reference and supporting data on the information provided visit www.MyriadPro.com/References.

* Management based on medical society guidelines. For these individual society guidelines go to www.MyradTests.com/Patient_Guidelines.

** Based on research at time of product launch, riskScore™ is only calculated for women of solely European Ancestry under the age of 85 and without a personal history of breast cancer, LCIS, hyperplasia, atypical hyperplasia, or a breast biopsy of unknown results. riskScore is not calculated if a woman or a blood relative is known to carry a mutation in a breast cancer risk gene.